Meitav Dash Investments Ltd. Takes Position in AbbVie Inc. (NYSE:ABBV)
Meitav Dash Investments Ltd. Takes Position in AbbVie Inc. (NYSE:ABBV)
Meitav Dash Investments Ltd. purchased a new position in shares of AbbVie Inc. (NYSE:ABBV – Get Rating) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 9,741 shares of the company's stock, valued at approximately $1,579,000.
据艾伯维公司在最近提交给美国证券交易委员会(Securities&Exchange Commission)的文件中说，该公司在第一季度购买了新的艾伯维公司股票头寸。该公司购买了9,741股该公司股票，价值约1,579,000美元。
Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. lifted its position in AbbVie by 1.1% during the fourth quarter. BlackRock Inc. now owns 128,197,554 shares of the company's stock worth $17,357,949,000 after acquiring an additional 1,358,115 shares during the last quarter. State Street Corp lifted its position in AbbVie by 3.4% during the fourth quarter. State Street Corp now owns 79,357,705 shares of the company's stock worth $10,745,033,000 after acquiring an additional 2,597,076 shares during the last quarter. Geode Capital Management LLC lifted its position in AbbVie by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 28,518,946 shares of the company's stock worth $3,850,573,000 after acquiring an additional 758,354 shares during the last quarter. Norges Bank acquired a new stake in AbbVie during the fourth quarter worth approximately $2,433,269,000. Finally, Nuveen Asset Management LLC raised its position in shares of AbbVie by 12.2% in the fourth quarter. Nuveen Asset Management LLC now owns 16,331,749 shares of the company's stock valued at $2,211,319,000 after buying an additional 1,771,090 shares in the last quarter. Institutional investors own 67.03% of the company's stock.
其他对冲基金和其他机构投资者也买卖了该公司的股票。贝莱德股份有限公司在第四季度将其在艾伯维的持仓提高了1.1%。贝莱德股份有限公司在上个季度增持了1,358,115股后，目前持有128,197,554股该公司股票，价值17,357,949,000美元。道富集团在第四季度将其在AbbVie的头寸提高了3.4%。道富银行目前持有79,357,705股该公司股票，价值10,745,033,000美元，上一季度又收购了2,597,076股。Geode Capital Management LLC在第四季度将其在AbbVie的头寸提高了2.7%。Geode Capital Management LLC在上个季度增持了758,354股后，现在拥有28,518,946股该公司股票，价值3,850,573,000美元。挪威银行在第四季度收购了AbbVie的新股份，价值约2433269,000美元。最后，Nuveen Asset Management LLC在第四季度将其在AbbVie股票的持仓提高了12.2%。Nuveen Asset Management LLC现在拥有16,331,749股该公司股票，价值2,211,319,000美元，上个季度又购买了1,771,090股。机构投资者持有该公司67.03%的股份。
Analyst Ratings Changes
分析师评级发生变化
Several research analysts have commented on ABBV shares. Piper Sandler lowered their price objective on shares of AbbVie from $160.00 to $155.00 in a research report on Friday, July 29th. The Goldman Sachs Group boosted their price objective on shares of AbbVie from $122.00 to $140.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 12th. SVB Leerink assumed coverage on shares of AbbVie in a report on Monday, May 23rd. They issued an "underperform" rating and a $140.00 target price on the stock. Morgan Stanley dropped their price objective on shares of AbbVie from $191.00 to $188.00 and set an "overweight" rating on the stock in a report on Monday, August 1st. Finally, Wells Fargo & Company upped their price objective on shares of AbbVie from $165.00 to $200.00 in a report on Monday, May 2nd. One research analyst has rated the stock with a sell rating, six have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $160.50.
几位研究分析师对ABBV的股票发表了评论。在7月29日星期五的一份研究报告中，派珀·桑德勒将艾伯维的股票目标价从160.00美元下调至155.00美元。高盛夫妇将艾伯维股票的目标价从122.00美元上调至140.00美元，并在周二的一份研究报告中给予该股“中性”评级。SVB Leerink在5月23日星期一的一份报告中对AbbVie的股票进行了报道。他们对该股给予了“表现不佳”的评级和140.00美元的目标价。在8月1日周一的一份报告中，摩根士丹利将艾伯维股票的目标价从191.00美元下调至188.00美元，并对该股设定了“增持”评级。最后，富国银行在5月2日星期一的一份报告中将艾伯维股票的目标价从165.00美元上调至200.00美元。一名研究分析师对该股的评级为卖出，6名分析师发布了持有评级，9名分析师给予了买入评级，一名分析师给予了该公司强烈的买入评级。根据MarketBeat.com的数据，该股目前的普遍评级为“适度买入”，平均目标价为160.50美元。
AbbVie Stock Performance
艾伯维股票表现
AbbVie (NYSE:ABBV – Get Rating) last posted its quarterly earnings data on Friday, July 29th. The company reported $3.37 earnings per share for the quarter, beating the consensus estimate of $3.31 by $0.06. The firm had revenue of $14.58 billion for the quarter, compared to analysts' expectations of $14.64 billion. AbbVie had a net margin of 22.03% and a return on equity of 157.31%. The business's quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the company posted $3.11 EPS. On average, equities research analysts expect that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.
艾伯维(纽约证券交易所代码：ABBV-GET Rating)上一次公布季度收益数据是在7月29日星期五。该公司公布本季度每股收益为3.37美元，比普遍预期的3.31美元高出0.06美元。该公司当季营收为145.8亿美元，高于分析师预期的146.4亿美元。艾伯维的净利润率为22.03%，股本回报率为157.31%。该业务的季度收入同比增长了4.5%。去年同期，该公司公布的每股收益为3.11美元。股票研究分析师平均预计，AbbVie Inc.本财年每股收益为14.05美元。
AbbVie Dividend Announcement
AbbVie股息公告
The firm also recently announced a quarterly dividend, which will be paid on Monday, August 15th. Investors of record on Friday, July 15th will be issued a dividend of $1.41 per share. This represents a $5.64 annualized dividend and a dividend yield of 4.09%. The ex-dividend date is Thursday, July 14th. AbbVie's dividend payout ratio is currently 79.89%.
该公司最近还宣布了季度股息，将于8月15日星期一支付。7月15日(星期五)登记在册的投资者将获得每股1.41美元的股息。这意味着年化股息为5.64美元，股息收益率为4.09%。除股息日期为7月14日星期四。艾伯维的股息支付率目前为79.89%。
Insider Activity at AbbVie
艾伯维的内幕活动
In other AbbVie news, EVP Henry O. Gosebruch sold 83,960 shares of the firm's stock in a transaction on Monday, May 16th. The shares were sold at an average price of $155.00, for a total value of $13,013,800.00. Following the sale, the executive vice president now owns 16,623 shares of the company's stock, valued at approximately $2,576,565. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other AbbVie news, Vice Chairman Michael Severino sold 100,000 shares of the firm's stock in a transaction on Monday, May 9th. The shares were sold at an average price of $150.28, for a total value of $15,028,000.00. Following the sale, the insider now owns 152,103 shares of the company's stock, valued at approximately $22,858,038.84. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Henry O. Gosebruch sold 83,960 shares of AbbVie stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $155.00, for a total transaction of $13,013,800.00. Following the sale, the executive vice president now directly owns 16,623 shares in the company, valued at approximately $2,576,565. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 363,761 shares of company stock valued at $55,528,771. Insiders own 0.08% of the company's stock.
在AbbVie的其他新闻中，执行副总裁Henry O.Gosebruch在5月16日星期一的一笔交易中出售了83,960股公司股票。这些股票的平均价格为155.00美元，总价值为13,013,800.00美元。出售股份后，执行副总裁总裁现在持有该公司16623股股票，价值约2576565美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，可以通过这个超级链接获得。在AbbVie的其他新闻中，副董事长Michael Severino在5月9日星期一的一笔交易中出售了10万股公司股票。这些股票的平均价格为150.28美元，总价值为150,028,000.00美元。出售后，这位内部人士现在拥有152,103股该公司股票，价值约22,858,038.84美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，可以通过这个超级链接获得。此外，执行副总裁亨利·O·古斯布鲁赫在5月16日星期一的交易中出售了83,960股AbbVie股票。这些股票以155.00美元的平均价格出售，总成交金额为13,013,800.00美元。出售后，执行副总裁总裁现在直接持有该公司16,623股股份，价值约2,576,565美元。此次拍卖的披露信息可在此处找到。在过去的90天里，内部人士出售了363,761股公司股票，价值55,528,771美元。内部人士持有该公司0.08%的股份。
AbbVie Profile
AbbVie个人资料
(Get Rating)
(获取评级)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
艾伯维公司在世界各地发现、开发、制造和销售药品。该公司提供HUMIRA，用于注射治疗自身免疫和肠道Behçet‘s疾病；SKYRIZI用于治疗成人中到重度斑块型牛皮癣；RINVOQ，用于治疗成人患者的中到重度活动性类风湿性关节炎；IMBRUVICA，用于治疗成人慢性淋巴细胞白血病和小淋巴细胞淋巴瘤；以及VENCLEXTA，用于治疗成人慢性丙型肝炎病毒基因1-6感染。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on AbbVie (ABBV)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- 免费获取StockNews.com关于AbbVie的研究报告(ABBV)
- MarketBeat：回顾中的一周8/1-8/5
- 如何利用高贝塔系数股票最大化你的投资利润
- 克罗诺斯集团(Cronos Group Inc.)营收上升，是时候收购了吗？
- 苹果为何可能在年底创下历史新高
- Beyond Meat不是没有希望，而且它很便宜
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Get Rating).
想看看其他对冲基金持有ABBV吗？访问HoldingsChannel.com获取艾伯维公司的最新13F文件和内幕交易。
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
接收AbbVie Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对AbbVie和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。